PTPRM is an important component of STAT3 regulation with downstream effects on proliferation and metastasis in lung cancer [84] therefore we speculated whether PTPRM epigenetically deficient cancer cells could be exploited for therapeutic purposes, specifically drugs that target the JAK/STAT cell signalling pathway in other tissues. This evidence concerns the gene STAT3 and lung carcinoma.